GET DAILY SIGNALSInspireMD (NSPR): Analyst Targets Suggest Potential for +320% Gains to Reach $3.30
Key Takeaways
- The central $3.30 stock price target is the arithmetic mean of the three verified current analyst price targets reviewed (range $3.00 to $4.00), rounded to a reader-friendly level.
- At a recent price near $0.78, reaching $3.30 would require upside of roughly 320% — a very large move that would more than quadruple the share price.
- All three covering firms rate NSPR Buy or Overweight, even after cutting targets in 2026, reflecting continued optimism about the U.S. commercial opportunity.
- Key supports include a path to FDA clearance for the CGuard delivery system and an 80-centimeter transcarotid system that could expand the addressable market.
- The biggest risks are regulatory uncertainty, a 2026 voluntary recall and commercialization pause, withdrawn revenue guidance, ongoing losses, and dilution from a proposed public offering.
- For more context, explore InspireMD's Major News and Today's Price Move, its AI-driven Forecast, and its upcoming Earnings page.
- For additional signals and screening tools, explore Trending AI Robots.
What the Analyst Targets Show for NSPR
Coverage of this small-cap remains limited. Three firms currently publish 12-month targets on NSPR, all with bullish ratings. Piper Sandler (analyst Adam Maeder) carries an Overweight rating with a $3.00 target, lowered from $4.00 in May 2026. Maxim Group, which initiated coverage at $6.00 in February 2026, has trimmed its Buy-rated target to $3.00. Lake Street (analyst Frank Takkinen) holds the high end at $4.00, reiterated as Buy.
The arithmetic mean of these three verified targets is approximately $3.33, which rounds to the $3.30 central target used here; the low-to-high range is $3.00 to $4.00. Because targets have been revised at different times, independent aggregators have shown a slightly higher average near $3.67 as well. The $3.30 figure is the author's own calculation from the three current targets, not an officially published consensus. The relatively narrow $3.00–$4.00 band, despite the enormous implied upside, reflects shared conviction in the U.S. market opportunity rather than precise near-term valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Position and the Road to the Target
With the stock recently trading near $0.78, moving to $3.30 would represent roughly 320% appreciation — a very large move that would require a fundamental re-rating of the company. InspireMD's lead product, CGuard Prime, received FDA approval and launched in the U.S. in July 2025. The company has since navigated a voluntary recall of its CGuard Prime 135 cm delivery system over technical performance issues (not patient safety), pausing U.S. commercialization and withdrawing full-year 2026 revenue guidance. Management has pointed to potential FDA clearance of the original delivery system in the third quarter of 2026, with the 80 cm system for transcarotid revascularization still under review.
Factors That Could Support a Move Higher
The bull case rests on regulatory and commercial execution. InspireMD estimates a combined addressable market of roughly $1.3 billion for its CGuard and SwitchGuard systems, and the roughly 35,000 annual transcarotid artery revascularization (TCAR) procedures could meaningfully expand demand if the 80 cm system is cleared. Revenue grew more than 120% year over year to $3.4 million in the first quarter of 2026, and the company's SwitchGuard neuroprotection system, with a pivotal trial now approved by the FDA, is targeted for a U.S. launch in 2027. Analyst Buy ratings reflect the view that the shares discount a worst-case regulatory outcome while understating the long-term opportunity. From what I see, these catalysts remain the key drivers to monitor.
Risks That Could Keep the Target Out of Reach
The risks are substantial. The 135 cm recall and commercialization pause disrupted the U.S. ramp and forced the withdrawal of 2026 guidance; the company also flagged roughly $700,000 in customer-return reserves and $650,000 in inventory impairment and remediation costs. InspireMD remains deeply unprofitable, reporting negative EPS (earnings per share), and competes against far larger rivals including Abbott (ABT), Medtronic (MDT), and Boston Scientific (BSX). A proposed public offering of up to $75 million announced in November 2026 adds dilution risk. Any further regulatory delay or setback could compress the multiple further and keep the target out of reach.
Technical Levels Worth Watching
NSPR trades near the lower end of a wide 52-week range of roughly $0.43 to $2.22. The $1.00 level stands as a notable psychological barrier, with prior highs above $2.00 representing longer-term resistance zones. Because the stock is thinly traded and event-driven, price action has historically been dominated by FDA decisions and capital raises rather than conventional technical structure, which makes discrete catalysts more important than chart patterns. I’m watching this closely for any shifts in momentum.
Time Horizon and Key Items to Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though individual assumptions on regulatory timing differ. Investors should watch FDA decisions on the CGuard delivery system and the 80 cm system, quarterly revenue and cash-burn trends, any update to withdrawn guidance, terms of the proposed equity offering, and analyst target revisions. The company's earnings date and the outcome of the public offering are near-term focal points, but no definitive forecast on timing or the eventual share price is offered here.
Using AI Daily Buy/Sell Signals for Perspective
In my analysis of event-driven names like this, I often turn to automated tools for an extra layer of data. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders identify emerging opportunities, track positions, and detect shifting trends more efficiently than manual screening. For a volatile, event-driven name like NSPR, automated signals can provide an additional, data-driven layer of perspective alongside fundamental research.
Overall View on Reaching the Target
Can NSPR reach $3.30? The central target — the average of three current analyst targets spanning $3.00 to $4.00 — implies roughly 320% upside from a recent price near $0.78, a very large move that is fundamentally tied to FDA clearances and a successful U.S. commercial relaunch. The bull case rests on a large addressable market and new product catalysts, while the bear case centers on regulatory binary risk, the 2026 recall, withdrawn guidance, ongoing losses, and dilution. Analyst disagreement is modest in direction but meaningful in level, and the outcome depends more on regulatory milestones than on current financial results. No guarantee of reaching the target is offered, and the path remains highly speculative.
Exploring Tickeron AI Tools for Research
One tool I have found useful in my own work is Tickeron’s AI Daily Buy/Sell Signals. It applies AI to scan market data and technical patterns across many securities, delivering signals that can complement traditional research. The platform also offers related features like pattern recognition and trend engines that help surface ideas in real time. I typically review these alongside fundamentals when evaluating names with binary catalysts. This approach has helped me organize thoughts on timing and risk without replacing core analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NSPR in upward trend: 10-day moving average crossed above 50-day moving average on November 11, 2026
The 10-day moving average for NSPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 18 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on NSPR as a result. In 76 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for NSPR just turned positive on October 23, 2026. Looking at past instances where NSPR's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
NSPR moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +12.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where NSPR advanced for three days, in 152 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for NSPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NSPR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NSPR entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.035) is normal, around the industry mean (4.142). P/E Ratio (-1.141) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.767) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NSPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medical devices
Industry MedicalNursingServices
Advertisement